B. A. Howell - DILIsym Serv Inc | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 14 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling

J. L. Woodhead, L. Pellegrini,L. K. M. Shoda,B. A. Howell

Pharmaceutical Research（2020）

引用21浏览0WOS引用

MECHANISTIC MODELING AND HEPATIC BIOMARKER DATA FROM GGF2 (CIMAGLERMIN ALFA)-TREATED SUBJECTS IN PHASE I CLINICAL TRIALS SUGGEST LOW LIKELIHOOD OF PROGRESSIVE LIVER INJURY

D. M. Longo,G. T. Generaux,B. A. Howell,S. Q. Siler,D. J. Antoine,D. Button,A. Caggiano,A. Eisen,J. F. Iaci, R. Stanulis,P. B. Watkins

CLINICAL PHARMACOLOGY & THERAPEUTICSno. S1 (2017): S75-S75

引用0浏览0引用

Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials

D. M. Longo,G. T. Generaux,B. A. Howell,S. Q. Siler,D. J. Antoine,D. Button,A. Caggiano,A. Eisen,J. Iaci, R. Stanulis,T. Parry,M. Mosedale,P. B. Watkins

Clinical pharmacology and therapeutics/Clinical pharmacology & therapeuticsno. 6 (2017): 961-969

引用34浏览0WOS引用

QSP MODELING OF LIVER AMPK ACTIVATION USING NAFLDSYM IS PREDICTED TO REDUCE STEATOSIS IN NAFLD PATIENTS

G. Generaux,T. R. Rieger,B. A. Howell,R. Allen,C. J. Musante,P. B. Watkins,S. Q. Siler

CLINICAL PHARMACOLOGY & THERAPEUTICSno. S1 (2017): S65-S65

引用0浏览0引用

USING SYSTEMS PHARMACOLOGY MODELING TO UNDERSTAND THE PATHOPHYSIOLOGY OF NAFLD AND RESPONSE TO DIETARY INTERVENTION IN A SIMULATED POPULATION

S. Q. Siler,T. R. Rieger,G. Generaux,B. A. Howell,R. Allen,C. J. Musante,P. B. Watkins

CLINICAL PHARMACOLOGY & THERAPEUTICSno. S1 (2017): S88-S88

引用0浏览0引用

Prospective Liver Safety Comparison of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Using Quantitative Systems Toxicology Modeling

J. L. Woodhead, L. Pellegrini,S. Q. Siler,L. K. M. Shoda,P. B. Watkins,B. A. Howell

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICSno. SUPnan (2017): S70-S71

引用0浏览0引用

QSP MODELING OF LIVER DGAT INHIBITION USING NAFLDSYM IS PREDICTED TO REDUCE STEATOSIS BUT MAY NOT RELIEVE LIPOTOXICITY IN NAFLD PATIENTS

T. R. Rieger,G. Generaux,B. A. Howell,R. Allen,C. J. Musante,P. B. Watkins,S. Q. Siler

CLINICAL PHARMACOLOGY & THERAPEUTICSno. S1 (2017): S85-S85

引用0浏览0引用

Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone with DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury

D. M. Longo, Y. Yang,P. B. Watkins,B. A. Howell,S. Q. Siler

CPT Pharmacometrics & Systems Pharmacologyno. 1 (2016): 31-39

引用56浏览0WOS引用

MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics

Y. Yang,S. Nadanaciva,Y. Will,J. L. Woodhead,B. A. Howell,P. B. Watkins,S. Q. Siler

Pharmaceutical Research（2015）

引用35浏览0WOS引用

Quantitative Systems Modeling Provides Biological Plausibility for Potential Mechanisms of Tolvaptan-Induced Hepatotoxicity

J. L. Woodhead, W. Brock, S. Roth,K. L. R. Brouwer,S. Q. Siler, R. C. Church,P. B. Watkins, S. E. Shoaf,B. A. Howell,L. K. M. Shoda

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS（2015）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn